Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines
NCT07493460Phase 4Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of trivalent inactivated influenza vaccine, tetanus toxoid + diphtheria toxoid + acellular pertussis, recombinant human papillomavirus 9-valent vaccine, Hepatitis A virus vaccine in influenza, Tetanus, diphtheria, pertussis, human papillomavirus infection, sponsored by Washington University School of Medicine. Started Aug 2025; status: active, not recruiting.
02
Drugs
trivalent inactivated influenza vaccinetetanus toxoid + diphtheria toxoid + acellular pertussisrecombinant human papillomavirus 9-valent vaccineHepatitis A virus vaccine
03
Conditions
influenzaTetanusdiphtheriapertussishuman papillomavirus infection
Beyond the preview
Go deeper on NCT07493460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493460.